CRISPR reports CTX320 Lp(a) reduction up to 73% in Phase 1 dose escalation; CTX321 shows 2x greater potency

CRISPR Therapeutics

CRISPR Therapeutics reported that CTX320 achieved up to 73% reduction in Lp(a) in Phase 1 dose escalation, with a Phase 1b/2a update expected in H1 2026. The company is also advancing CTX321, a next-generation LPA program incorporating an improved guide RNA with approximately 2x greater potency in preclinical testing, which is in IND-enabling studies.

• CTX320 dose escalation shows 73% Lp(a) reduction
• First-in-class in vivo LPA gene editing approach
• CTX321 next-gen program shows 2x potency advantage
• Addresses cardiovascular disease affecting ~20% of global population